CAMP and rosacea: Other clinical trials have investigated the inhibitory effects of topical ivermectin on serine protease activity, LL-37 production, and the skin microbiome of individuals with rosacea and during rosacea-specific inflammation (trial ID: NCT02806414), or evaluated the effect of topical aminocaproic acid in inhibiting KLK5 serine protease activity and LL-37 production during rosacea-specific inflammation (trial ID: NCT01398280).